Tüdőrák: vizsgálatok itt: Franciaország
318 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 18.. Ask the study team whether a trial fits you.
- No phaseNot yet taking people in FranciaországRegistry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance
- Where
- Créteil, Lyon
- Életkor
- 18 év and over
- People
- 2000 worldwide
- Run by
- Mark C Burgmans, MD PhD
See details and how to joinNCT07636148 - 3. fázisTaking peopleStudy of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer
- Where
- Angers, Bron, Creteil Cedex, Grenoble Cedex 9, Lyon Cedex 04, Marseille, Paris, Pessac, Pierre-Bénite, Rennes Cedex 9, Saint-Herblain, Strasbourg, Villejuif
- Életkor
- 18 év and over
- People
- 355 worldwide
- Run by
- Gilead Sciences Inc.
See details and how to join2024-515884-69-00 - 2. fázisTaking peopleLuMIERE: A Phase 1/2, Multicenter, Open label, Non randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of [177Lu]Lu-FAP-2286 in Participants with an Advanced Solid Tumor
- Where
- Bordeaux, Clermont-Ferrand, Marseille, Montpellier Cedex 5, Vandoeuvre Les Nancy
- Életkor
- 18 év and over
- People
- 36 worldwide
- Run by
- Novartis Pharma AG
See details and how to joinNCT04939610 · EU 2023-508995-12-01 - 1/2. fázisTaking peopleStudy of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
- Where
- Bordeaux, Saint-Herblain Cedex
- Életkor
- 18 év to 100 év
- People
- 280 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06726148 · EU 2024-517281-42-00 - 3. fázisFut, nem toborozPhase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Where
- Marseille, Paris, Saint-Herblain Cedex, Strasbourg Cedex
- Életkor
- 18 év and over
- People
- 582 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06350097 · EU 2023-509883-89-00 - 1/2. fázisTaking peopleA Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
- Where
- Créteil, Marseille, Paris Cedex 13, Suresnes, Toulouse
- Életkor
- 18 év and over
- People
- 594 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT06892548 · EU 2024-520238-31-01 - 1. fázisTaking peopleStudy of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
- Where
- Bron, Marseille, Villejuif
- Életkor
- 18 év to 99 év
- People
- 160 worldwide
- Run by
- Amgen
See details and how to joinNCT07531095 · EU 2025-522888-15-00 - 3. fázisTaking peopleStudy to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- Where
- Bron, Caen Cedex 5, Lyon, Lyon Cedex 04, Marseille, Pierre-Bénite, Saint-Herblain, Saint-Herblain Cedex, Toulouse
- Életkor
- 18 év and over
- People
- 36 worldwide
- Run by
- Arrivent Biopharma Inc.
See details and how to join2025-522151-26-00 - 2. fázisTaking peoplePhase 2, Multicenter, Open label, Platform Study investigating Tarlatamab (AMG 757) in patients with Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), with biomarker analysis to characterize response/resistance (UNLOCK TARLATAMAB)
- Where
- Bordeaux, Nice Cedex 2, Villejuif
- Életkor
- 18 év and over
- People
- 41 worldwide
- Run by
- Institut Gustave Roussy
See details and how to join2024-515847-47-00 - 1. fázisTaking peopleA Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET kinase Inhibitor, DO-2 in Patients With Advanced or Refractory Solid Tumours
- Where
- Bordeaux, Lille Cedex, Lyon Cedex 08, Marseille, Nice Cedex 2, Rennes, Villejuif
- Életkor
- 18 év and over
- People
- 138 worldwide
- Run by
- Deuteroncology
See details and how to join2023-504897-39-00 - 3. fázisFut, nem toborozStudy Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLLphi-312)
- Where
- Creteil Cedex, Lyon, Marseille, Paris, Rouen Cedex, Saint-Herblain, Toulon Cedex 9, Toulouse
- Életkor
- 18 év and over
- People
- 156 worldwide
- Run by
- Amgen Inc.
See details and how to join2024-520050-38-00 - 2. fázisNot yet taking people in FranciaországPersonnalized Immunotherapy in Patients With Stage III Non-small Cell Lung Cancer
- Where
- Angers, Avignon, Bordeaux Cedex, Boulogne-Billancourt, Brest, Bron, Caen Cedex 9, Chambéry, Clermont Ferrand Cedex 1, Colmar Cedex, Grenoble Cedex 9, La Roche Sur Yon Cedex 9, Le Mans Cedex 9, Lille, Limoges Cedex 1, Marseille, Montpellier Cedex 5, Morlaix, Paris, Paris Cedex 13, Pessac Cedex, Poitiers, Reims, Saint-Herblain Cedex, Toulon Cedex 9, Tours, Vannes, Villefranche-sur-Saône
- Életkor
- 18 év and over
- People
- 177
- Run by
- Intergroupe Francophone de Cancerologie Thoracique
See details and how to joinNCT07759492 · EU 2025-522801-39-00 - 1/2. fázisTaking peopleA Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Where
- Villejuif
- Életkor
- 18 év and over
- People
- 366 worldwide
- Run by
- Marengo Therapeutics, Inc.
See details and how to joinNCT05592626 · EU 2023-505334-10-01 - 1/2. fázisTaking peopleA Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
- Where
- Clermont Ferrand Cedex1, Dijon, La Tronche, Lyon, Marseille, Nantes, Pessac, Toulouse Cedex 9, Vandoeuvre Les Nancy
- Életkor
- 18 év and over
- People
- 270 worldwide
- Run by
- Lumara Bio Oncologics GmbH
See details and how to joinNCT05706129 · EU 2023-504254-35-00 - 2. fázisTaking peopleAdjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer
- Where
- Angers, ANGERS, Avignon Cedex 9, Boulogne-Billancourt, Brest, Bron Cedex, Caen Cedex 5, Caen Cedex 9, Chambéry, Créteil, Dijon, LE HAVRE, Le Mans Cedex 2, Le Mans Cedex 9, Lille, Lyon Cedex 04, Marseille, Metz, Montivilliers, Mulhouse, Orléans, Paris, Paris Cedex 18, Paris Cedex 20, Pessac Cedex, Pierre-Bénite, Rennes, Rennes Cedex, Rouen, Rouen Cedex, Saint-Cloud, Saint-Herblain, Strasbourg, Suresnes, Thionville, Toulouse, TOULOUSE Cedex, Tours, Valence, Valenciennes, Vandouvre Les Nancy, Vantoux, Villejuif
- Életkor
- 18 év and over
- People
- 152
- Run by
- Intergroupe Francophone de Cancerologie Thoracique
See details and how to joinNCT06656598 · EU 2024-517316-29-00 - 2. fázisTaking peopleTreatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease
- Where
- Angers, Besancon Cedex, Bobigny Cedex, Boulogne-Billancourt, Boulogne-sur-Mer, Brest, Bron, Caen Cedex 9, Clermont Ferrand Cedex 1, Colmar Cedex, Créteil, Dijon, Epagny Metz-tessy, Grenoble Cedex 9, Lille, Marseille, Montpellier Cedex 5, Paris, Paris Cedex 13, Paris Cedex 18, Pessac, Rennes, Saint-Herblain, Strasbourg Cedex, Suresnes, Tours, Vantoux, Villefranche-sur-Saône
- Életkor
- 18 év and over
- People
- 108
- Run by
- Intergroupe Francophone de Cancerologie Thoracique
See details and how to joinNCT07420439 · EU 2025-522790-10-00 - 3. fázisTaking peopleA Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- Where
- Avignon, Bordeaux, Créteil, Lille Cedex, Limoges, Lyon, Marseille, Montpellier, Montpellier Cedex 5, Mulhouse, Paris, Paris Cedex 20, Rennes, Saint-Herblain, Saint-Priest-en-Jarez, Suresnes, Villejuif
- Életkor
- 18 év and over
- People
- 540 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06203210 · EU 2023-509628-16-00 - 2. fázisTaking peopleStudy Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance
- Where
- Bordeaux, Dijon, Marseille, Paris, Saint-Herblain, Vandœuvre-lès-Nancy, Villejuif
- Életkor
- 18 év and over
- People
- 60
- Run by
- Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT07483983 - 1. fázisTaking peopleStudy of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- Where
- Bordeaux, Villejuif
- Életkor
- 18 év and over
- People
- 307 worldwide
- Run by
- Xencor, Inc.
See details and how to joinNCT05433142 · EU 2024-513619-28-00 - 1. fázisTaking peopleAMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
- Where
- Lyon, Villejuif
- Életkor
- 18 év and over
- People
- 434 worldwide
- Run by
- Amgen
See details and how to joinNCT07094113 - 1. fázisTaking peoplePhase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- Where
- Bron, Villejuif
- Életkor
- 18 év to 100 év
- People
- 162 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06562192 - 2. fázisBefejeződöttDAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
- Where
- Créteil, Marseille, Paris, Strasbourg Cedex, Villejuif
- Életkor
- 18 év and over
- People
- 204 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT05882058 · EU 2023-504247-13-00 - 1. fázisTaking peopleA Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Where
- Bordeaux, Paris, Villejuif
- Életkor
- 18 év and over
- People
- 714 worldwide
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00 - 1. fázisTaking peopleA Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- Where
- Villejuif
- Életkor
- 18 év and over
- People
- 914 worldwide
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT06131840 · EU 2023-505858-18-00 - 1. fázisTaking peopleA Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- Where
- Lyon, Toulouse, Villejuif
- Életkor
- 18 év and over
- People
- 710 worldwide
- Run by
- Incyte Corporation
See details and how to joinNCT06179160 · EU 2023-507091-47-00